OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Frequently asked questions
What sector does OS Therapies Incorporated (OSTX) operate in?
OS Therapies Incorporated belongs to the Healthcare sector and operates in the Biotechnology industry.
What is OS Therapies Incorporated (OSTX) current stock price?
As of the latest data, OS Therapies Incorporated stock price is $1.21, with a previous close of $1.25. OS Therapies Incorporated lost -$0.04 in the last trading session, representing a -3.2% loss.
What is OS Therapies Incorporated (OSTX) current market capitalization?
OS Therapies Incorporated market cap is approximately 56.63 million.
What is OS Therapies Incorporated (OSTX) Earnings Per Share (EPS)?
The trailing EPS is -$1.09, and the forward EPS is $0.35.
What is OS Therapies Incorporated (OSTX) EBITDA?
OS Therapies Incorporated EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -8.45 million.
Does OS Therapies Incorporated (OSTX) pay dividends?
No. OS Therapies Incorporated does not pay a dividend.
When is OS Therapies Incorporated (OSTX) next earnings report?
OS Therapies Incorporated is expected to release its next earnings report on September 30, 2026.
What is OS Therapies Incorporated (OSTX) beta (volatility) score?
OS Therapies Incorporated has a beta of -0.677, indicating lower volatility than the overall market.
